Condition 1: Acute nasopharyngitis. Condition 2: Acute sinusitis. Condition 3: Acute pharyngitis. Condition 4: Acute tonsillitis. Condition 5: Acute laryngitis and tracheitis. Condition 6: Acute obstructive laryngitis [croup] and epiglottitis. Condition 7: Acute upper respiratory infections of multiple and unspecified sites. Acute nasopharyngitis [common cold] Acute sinusitis Acute pharyngitis Acute tonsillitis Acute laryngitis and tracheitis Acute obstructive laryngitis [croup] and epiglo
Conditions
Interventions
Intervention 1: Intervention group: The treatment group will take Jinhua Qinggan granules. Jinhua Qinggan granules were invented during the H1N1 pandemic in 2009 (SFDA Approval number: Chinese medicin
the prescription was designed by the Chinese and Western medical experts organized by the Beijing Administration of Traditional Chinese Medicine. Jinhua Qinggan granules doage: 5g/sachet
1 sachet each time, 3 times daily aftermeal, dissolve in boil water. The course of treatment is 5 days, and the visit points are set on the 1st and 5th day, in which the 5th day is follow-up. Patients
Sponsors
Asadabad University of Medical Sciences
Ju Xie Chang (Beijing) Pharmaceutical Co. Ltd
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Body Temperature > 37.5ºC and highest point <39ºC within 24hours of enrollment, Within 12 hours of screening, three or more of the following main symptoms: Nasal Congestion, Rhinorrhea, Sore and/or scratchy throat, sneezing, headache, muscle or body aches, or malaise. The subject has signed the informed consent form.
Exclusion criteria
Exclusion criteria: Other Respiratory diseases or acute and chronic nasal diseases or abnormal nasal mucosal function after nasal surgery or nasopharyngeal radiotherapy Severe primary health conditions associated with cardiovascular, cerebrovascular, pulmonary, hepatic, renal, endocrine and hematological diseases, hematopoietic system and mental illness or serious diseases affecting their survival, such as cancer or AIDS With severe cardiopulmonary dysfunction, cardiopulmonary insufficiency Subjects, who were treated with other Chinese and western drugs (including drugs for common cold, antiviral, antibiotics, and similar traditional Chinese medicine) and antipyretic and analgesic drugs within 6 hours before enrollment. Allergic individuals and those who are known to be allergic to experimental drugs. Pregnant women, and lactating women Subject, who has participated in the past 1 month in another clinical study. Subjects who are not suitable for the clinical trial based on investigators’ judgment. Subjects who consume alcohol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Curative Rate Evaluation. Timepoint: Measure the body temperature by treatment day 2/3/4/5. Method of measurement: In this study, data are obtained based on clinical and laboratory studies.;Lab tests (Improvement in Lymphocyte count, CRP, ESR levels etc.). Timepoint: Measurements will be taken before and after the treatment period. Method of measurement: In this study, data are obtained based on clinical and laboratory studies. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recovery time: disappearance of all symptoms of more than 24 hours. Timepoint: Measurements are performed before and after treatment. Method of measurement: By questionnaire, clinical and laboratory.;Defervescence rate (body temperature < 37 °C for more than 24 hours). Timepoint: Measurements are performed before, 2/3/4/5 after beginning of treatment, and after treatment. Method of measurement: By questionnaire, clinical and laboratory.;Defervescence start time: (Time between treatment and body temperature decrease 0.5°C for more than 24h). Timepoint: Measurements are performed before and after treatment. Method of measurement: By questionnaire, clinical and laboratory.;Recovery time of individual symptom. Timepoint: Measurements are performed before and after treatment. Method of measurement: By questionnaire, clinical and laboratory.;Disappearance of individual symptom (symptom score reach 1 or 0 for more than 24 hours). Timepoint: Measurements are performed before and after treatment. Method of measurement: By questionnaire, clinical and laboratory.;The quality of life of the product will be assessed by using the patient’s Quality of Life Assessment Questionnaire (QOL). Timepoint: Measurements are performed before and after treatment. Method of measurement: By questionnaire, clinical and laboratory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHemen Moradi-Sardareh
Asadabad University of Medical Sciences
Outcome results
None listed